AGN Algernon Pharmaceuticals Inc
- 0.120
- -0.005-4.00%
Algernon Pharmaceuticals Inc News
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke...
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch,...
Algernon Pharmaceuticals to Move Forward With Psychedelic Drug DMT Stroke Research Program as Its...
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company
Algernon Pharmaceuticals Inc. (AGN.CN) announced that Seyltx Inc., a privately owned U.S. based drug development company, has closed on its acquisition of Algernon's NP-120 (Ifenprodil) research progr
Press Release: Algernon Pharmaceuticals Announces Closing of the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position VANCOUVER, British Columbia, March 27, 2
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment | CSE:AGN, OTCQB:AGNPF
Algernon Pharmaceuticals Receives Notice of Intention to Grant From Chinese Patent Office for Repirinast to Treat CKD
Algernon Pharmaceuticals Inc. (AGN.CN), a Canadian clinical stage pharmaceutical development company, on Wednesday announced that it has received a notice of intention to grant from the Chinese Patent
Algernon Pharmaceuticals Announces Closing of Private Placement
Algernon Pharmaceuticals Announces Increase to Private Placement
Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant From Chinese Patent Office for Repirinast to Treat NASH and NAFLD
07:05 AM EST, 11/30/2023 (MT Newswires) -- Algernon Pharmaceuticals Brief: Says Received Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity Position
07:04 AM EST, 11/22/2023 (MT Newswires) -- Algernon Pharmaceuticals Brief: Announcing LOI for Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for US$2 Million and a 20% Equity P
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
Algernon Pharmaceuticals Inc. (AGN.CSE), a clinical stage pharmaceutical development company, on Wednesday said it has been issued a patent from the United States Patent and Trademark Office (USPTO),
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection With...
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 13.4% in April
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 33,100 shares, an
CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)
Toronto, Ontario--(Newsfile Corp. - le 21 avril/April 2023) - Algernon Pharmaceuticals Inc. Rights listed on March 28, 2023 will expire on April 27, 2023. Settlement Terms: All trades April 25 and 26
CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights
Toronto, Ontario--(Newsfile Corp. - Le 27 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a Rights Offering to eligible shareholders of record at the close of market on March 29, 2023.
CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)
Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Decreases By 26.3%
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 1,400 sha
